Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00755261 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Doxorubicin and Avastin® in Sarcoma.
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00755261 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 4 participants.
The verdict
NCT00755261, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This research is being done to find out if adding a drug called Avastin to an already approved regimen used for soft-tissue sarcoma, Doxorubicin, will improve overall survival, and slow disease progression. The study will also evaluate the overall safety of combining these drugs. It is not known if combining these drugs will improve outcome. Avastin has been approved for the treatment of metastatic carcinoma of the colon or rectum. It is not approved for the treatment of soft-tissue sarcoma when added to Doxorubicin.
Interventions
- DRUG Doxorubicin
- DRUG Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00755261
The ClinicalTrials.gov registry entry for NCT00755261 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxorubicin is the first listed.
NCT00755261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00755261 about?
NCT00755261 is a clinical study titled "Phase II Study of Doxorubicin and Avastin® in Sarcoma.". This research is being done to find out if adding a drug called Avastin to an already approved regimen used for soft-tissue sarcoma, Doxorubicin, will improve overall survival, and slow disease progression. The study will also evaluate the overall safety of combining these drugs. It is not known if ...
What is the current status of trial NCT00755261?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2008-09. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00755261?
The interventions under investigation include: Doxorubicin (DRUG), Avastin (DRUG).
Who is sponsoring clinical trial NCT00755261?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.